G Loncar1,2, B Bozic3,4, N Cvetinovic5, H-D Dungen6, M Lainscak7,8, S von Haehling9,10, W Doehner11, Z Radojicic12, B Putnikovic13,14, T Trippel6, V Popovic13,15. 1. Cardiology Department, Clinical Hospital Zvezdara, Dimitrija Tucovica 161, Belgrade, 11 000, Serbia. loncar_goran@yahoo.com. 2. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. loncar_goran@yahoo.com. 3. Institute for Medical Research, Military Medical Academy, Belgrade, Serbia. 4. Institute for Physiology and Biochemistry, University of Belgrade, Belgrade, Serbia. 5. Cardiology Department, Clinical Hospital Zvezdara, Dimitrija Tucovica 161, Belgrade, 11 000, Serbia. 6. Department of Cardiology, Campus Virchow, Charité Universitätsmedizin Berlin, Berlin, Germany. 7. Departments of Cardiology and Research and Education, General Hospital Celje, Celje, Slovenia. 8. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 9. Innovative Clinical Trials, Department of Cardiology and Pneumology, University of Medicine Göttingen, Göttingen, Germany. 10. Applied Cachexia Research, Department of Cardiology, Charité-University Medical School, Campus Virchow-Klinikum, Berlin, Germany. 11. Center for Stroke Research Berlin, Charite University Medical School, Berlin, Germany. 12. Institute for Statistics, Faculty of Organizational Sciences, University of Belgrade, Belgrade, Serbia. 13. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 14. Cardiology Department, Clinical Hospital Center Zemun, Belgrade, Serbia. 15. Institute of Endocrinology, Clinical Center of Serbia, Belgrade, Serbia.
Abstract
AIM: Evaluation of secondary hyperparathyroidism (SHPT) and its prognostic impact on all-cause mortality in elderly males with heart failure (HF). METHODS: Seventy three males (67 ± 7 years old) with systolic HF were included. Baseline PTH was measured. Patients were grouped according to PTH cut-off levels of 65 pg/ml (>65 pg/ml = SHPT vs. normal PTH). All-cause mortality was evaluated at 6-year follow-up. RESULTS: SHPT was diagnosed in 43 (59 %) patients. They were more severe compared to the patients with normal PTH regarding NYHA functional class (2.4 ± 0.5 vs. 2.1 ± 0.2, p = 0.001), quality of life score (34 ± 14 vs. 24 ± 12, p = 0.005), 6-min walking distance (378 ± 79 vs. 446 ± 73 m, p < 0.0001), left ventricular ejection fraction (27 ± 8 vs. 31 ± 7 %, p = 0.019), and NT-proBNP [2452 (3399) vs. 918 (1372) pg/ml, p < 0.0001]. No differences in age, vitamin D status, and renal function were noted between studied groups. A total of 41 (56 %) patients died within 6 years of follow-up. Kaplan-Meier survival analysis showed impaired long-term survival in patients with SHPT versus patients with normal PTH (p = 0.009). The rate of death was highest (75 %) in the group of patients with SHPT and NT-proBNP levels above median value (p = 0.003). Cox regression analysis demonstrated that NT-proBNP was the single independent predictor of all-cause mortality at 6-year follow-up [HR 3.698 (1.927-7.095), p < 0.0001]. CONCLUSION: SHPT was highly prevalent in elderly males with HF and was associated with impaired survival. HF patients with SHPT had more severe disease compared to the patients with normal serum PTH. Determination of serum PTH levels provided additional value to NT-proBNP for risk stratification in these patients.
AIM: Evaluation of secondary hyperparathyroidism (SHPT) and its prognostic impact on all-cause mortality in elderly males with heart failure (HF). METHODS: Seventy three males (67 ± 7 years old) with systolic HF were included. Baseline PTH was measured. Patients were grouped according to PTH cut-off levels of 65 pg/ml (>65 pg/ml = SHPT vs. normal PTH). All-cause mortality was evaluated at 6-year follow-up. RESULTS: SHPT was diagnosed in 43 (59 %) patients. They were more severe compared to the patients with normal PTH regarding NYHA functional class (2.4 ± 0.5 vs. 2.1 ± 0.2, p = 0.001), quality of life score (34 ± 14 vs. 24 ± 12, p = 0.005), 6-min walking distance (378 ± 79 vs. 446 ± 73 m, p < 0.0001), left ventricular ejection fraction (27 ± 8 vs. 31 ± 7 %, p = 0.019), and NT-proBNP [2452 (3399) vs. 918 (1372) pg/ml, p < 0.0001]. No differences in age, vitamin D status, and renal function were noted between studied groups. A total of 41 (56 %) patients died within 6 years of follow-up. Kaplan-Meier survival analysis showed impaired long-term survival in patients with SHPT versus patients with normal PTH (p = 0.009). The rate of death was highest (75 %) in the group of patients with SHPT and NT-proBNP levels above median value (p = 0.003). Cox regression analysis demonstrated that NT-proBNP was the single independent predictor of all-cause mortality at 6-year follow-up [HR 3.698 (1.927-7.095), p < 0.0001]. CONCLUSION: SHPT was highly prevalent in elderly males with HF and was associated with impaired survival. HF patients with SHPT had more severe disease compared to the patients with normal serum PTH. Determination of serum PTH levels provided additional value to NT-proBNP for risk stratification in these patients.
Authors: B Bozic; G Loncar; N Prodanovic; T Lepic; Z Radojicic; V Cvorovic; S Dimkovic; V Popovic Journal: Physiol Res Date: 2011-07-19 Impact factor: 1.881
Authors: G Loncar; B Bozic; S Dimkovic; N Prodanovic; Z Radojicic; V Cvorovic; B Putnikovic; V Popovic Journal: J Endocrinol Invest Date: 2010-09-02 Impact factor: 4.256
Authors: Kevin Damman; Mattia A E Valente; Adriaan A Voors; Christopher M O'Connor; Dirk J van Veldhuisen; Hans L Hillege Journal: Eur Heart J Date: 2013-10-27 Impact factor: 29.983
Authors: Nisha Bansal; Leila Zelnick; Cassianne Robinson-Cohen; Andy N Hoofnagle; Joachim H Ix; Joao A Lima; Abigail B Shoben; Carmen A Peralta; David S Siscovick; Bryan Kestenbaum; Ian H de Boer Journal: J Am Heart Assoc Date: 2014-12-02 Impact factor: 5.501
Authors: Catarina Magalhães Porto; Vanessa De Lima Silva; João Soares Brito da Luz; Brivaldo Markman Filho; Vera Magalhães da Silveira Journal: ESC Heart Fail Date: 2017-08-17